News & Updates

Addressing the obesity challenge with semaglutide

Obesity is a global epidemic that is on the rise in Singapore. One in five adults will be living with obesity in 2025, with disastrous consequences. Early intervention with semaglutide could help.

Rapid point-of-care testing enables timely and targeted RTI treatment

According to the 2021 Global Burden of Disease (GBD) study, COVID-19 and lower respiratory tract infections (LRTIs) ranked as the 1st and 5th leading causes of global disease burden across all age groups and genders.

Rapid point-of-care tests (POCTs) enable timely diagnosis, particularly in vulnerable populations at higher risk of severe illness, complications, and hospitalization. 

Product Highlight - LUCONAC

Luliconazole 5% w/w topical solution

Vaccination crucial to integrated dengue prevention and control in SEA

Southeast Asia (SEA) is one of the hotspots for dengue infections, with Indonesia and Thailand among the highly endemic countries. At a Takeda-sponsored symposium held during the 2nd APIC-ADVA Asia Pacific Summit on Infectious Diseases and Immunization in Singapore, experts focused on vaccination as an integral component of a holistic dengue prevention and control strategy in SEA.

*The editorial below is supported by Takeda Pharmaceuticals International AG Singapore Branch and is intended solely for informational purposes. Takeda has not influenced or contributed to the editorial content. While Takeda has provided financial support for the editorial, Takeda shall not be held responsible or liable for any errors, omissions, or inaccuracies in such information.

Momelotinib: A game-changer for managing myelofibrosis with anaemia

On November 1, 2024, the Singapore Health Sciences Authority (HSA) approved momelotinib for treating myelofibrosis in adult patients with moderate-to-severe anaemia who are either JAK inhibitor-naïve or have been treated with ruxolitinib. The approval was based on data from three pivotal trials — SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM. [Health Sciences Authority. Momelotinib (Omjjara) product information leaflet 2024]

This article explores the burden of anaemia in myelofibrosis, the evidence supporting momelotinib, and insights from renowned expert Dr Yvonne Loh, Haematologist at Curie Oncology, Singapore, on the challenges of treating myelofibrosis and momelotinib’s evolving role. 

Role of CGRP in acute migraine treatment and prevention: Evolving strategies and regional insights

This article highlights key insights from the Asia Migraine Healers Academy 2025, a Pfizer-organized event in Kuala Lumpur, Malaysia, where renowned experts Professor Andrew Charles (US) and Dr Mianwang He (China) discussed advancements in migraine management.

Evidence-based strategies to optimise the management of respiratory diseases

On 9 November 2024, GSK organised the 2024 Respiratory Summit: Breath Easy, Live Fully under the auspices of the Singapore Thoracic Society. The summit featured presentations from esteemed experts, Dr Chew Si Yuan and Dr Steve Yang, who discussed recent updates to the guidelines for respiratory diseases – such as chronic obstructive pulmonary disease (COPD), asthma and respiratory syncytial virus (RSV) infections – and strategies to optimise patient outcomes. The session was chaired by Dr Jim Teo.

Positioning ceftazidime-avibactam in managing difficult-to-treat P. aeruginosa infections in critically ill patients

In a Pfizer-sponsored webinar reaching audiences in Malaysia, Singapore, Indonesia, and the Philippines, Dr Alex Soriano, Consultant in Infectious Diseases at the Clinical and Provincial Hospital of Barcelona, Spain, discussed the pivotal role of ceftazidime/avibactam in treating multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) infections in critically ill patients.

A holistic approach to atopic dermatitis: Skin barriers, core therapies and adjunctive strategies

During the first Breakfast Symposium at the 33rd Singapore Pharmacy Congress on 5 October 2024, Dr Lucinda Tan emphasised the importance of maintaining a healthy skin barrier in patients with atopic dermatitis (AD) and provided an overview of the available management and treatment options.

Product Highlight - LYPSTAPLUS

Rosuvastatin + Ezetimibe 10/10 mg and 20/10 mg film-coated tablet